pocketful logo light
pocketful logo light
Parnax Lab Ltd logo

Parnax Lab Ltd

NSE: BSE: 506128

₹142.95

(5.95%)

Sun, 31 May 2026, 11:36 pm

mtf coin illustrationMTF 5x

Parnax Lab Analysis

dividend

thumbs up icon

Pros

    thumbs up icon

    Cons

    • Unable to evaluate Parnax Lab's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
    • Unable to evaluate Parnax Lab's dividend against the top 25% market benchmark as the company has not reported any payouts.

    health

    thumbs up icon

    Pros

    • Parnax Lab is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
    • Parnax Lab has been profitable on average in the past, therefore cash runway is not a concern.
    • Parnax Lab has been profitable on average in the past, therefore cash runway is not a concern.
    • Debt is well covered by operating cash flow (21.9%, greater than 20% of total debt).
    • Debt is covered by short term assets, assets are 1x debt.
    • Parnax Lab's cash and other short term assets cover its long term commitments.
    • The level of debt compared to net worth has been reduced over the past 5 years (138.8% vs 109.9% today).
    thumbs up icon

    Cons

    • Parnax Lab is making a loss, therefore interest payments are not well covered by earnings.
    • Parnax Lab's level of debt (109.9%) compared to net worth is high (greater than 40%).
    • High level of physical assets or inventory.

    management

    thumbs up icon

    Pros

    • The tenure for the Parnax Lab board of directors is about average.
    • Prakash's remuneration is about average for companies of similar size in India.
    • The tenure for the Parnax Lab management team is about average.
    thumbs up icon

    Cons

    • Prakash's compensation has increased whilst company is loss making.

    misc

    thumbs up icon

    Pros

      thumbs up icon

      Cons

      • Parnax Lab is not covered by any analysts.
      • Parnax Lab has significant price volatility in the past 3 months.

      past

      thumbs up icon

      Pros

        thumbs up icon

        Cons

        • Unable to compare Parnax Lab's 1-year earnings growth to the 5-year average as it is not currently profitable.
        • Parnax Lab does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
        • Parnax Lab used its assets less efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
        • It is difficult to establish if Parnax Lab improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
        • It is difficult to establish if Parnax Lab has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
        • Unable to compare Parnax Lab's 1-year growth to the IN Pharmaceuticals industry average as it is not currently profitable.

        value

        thumbs up icon

        Pros

        • Parnax Lab is good value based on assets compared to the IN Pharmaceuticals industry average.
        thumbs up icon

        Cons

        • Parnax Lab is loss making, we can't compare its value to the IN Pharmaceuticals industry average.
        • Parnax Lab is loss making, we can't compare the value of its earnings to the India market.
        • 506128 underperformed the Pharmaceuticals industry which returned 26.7% over the past year.
        • 506128 underperformed the Market in India which returned -14.5% over the past year.
        • BSE:506128 is down -12.3% underperforming the Pharmaceuticals industry which returned 6.8% over the past month.
        • BSE:506128 is down -12.3% underperforming the market in India which returned 8% over the past month.